|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005961,
umls-concept:C0017262,
umls-concept:C0054949,
umls-concept:C0087111,
umls-concept:C0185117,
umls-concept:C0728938,
umls-concept:C0856825,
umls-concept:C0871261,
umls-concept:C1420812,
umls-concept:C1514307,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2745955,
umls-concept:C2911684,
umls-concept:C2911692
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
1999-8-20
|
|
pubmed:abstractText |
CD134 (OX40) is a member of the tumor necrosis factor family which is expressed by activated T lymphocytes. CD134 expression on T cells was monitored during the first 35 days post-transplant in 14 patients, receiving either an HLA-identical sibling bone marrow transplant (BMT), a matched unrelated transplant (MUD-BMT) or an autologous peripheral blood progenitor cell transplant (PBPCT). The sibling and unrelated grafts were partially depleted of T cells. CD134 expression on CD4+ T cells peaked between 7 and 14 days after BMT, with a mean peak value of 45% of CD4+ cells (range 26-70%) over all three patient groups. The observed pattern of CD4+ CD134+ expression, an increase during the first 2 weeks post-BMT followed by a gradual decline towards values of 15-40%, was similar in all groups. No difference in the kinetics of CD134 expression by CD4+ T cells was observed between the patients that did or did not develop graft-versus-host disease (GVHD), nor did the clinical effect of any treatment given for GVHD correlate with alterations in CD134 expression by CD4+ T cells. Absolute CD4+,CD134+ T cell numbers showed a more rapid increment after autologous PBPCT than after sibling or MUD transplants. We conclude that expression of CD134+ by CD4+ T lymphocytes cannot serve as a surrogate marker for allo-reactivity. CD134+ expression may reflect lymphocyte regeneration, rather than alloreactivity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0268-3369
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1013-7
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10373067-Acute Disease,
pubmed-meshheading:10373067-Adult,
pubmed-meshheading:10373067-Aged,
pubmed-meshheading:10373067-Antigens, CD27,
pubmed-meshheading:10373067-Biological Markers,
pubmed-meshheading:10373067-Bone Marrow Transplantation,
pubmed-meshheading:10373067-CD4-Positive T-Lymphocytes,
pubmed-meshheading:10373067-CD8-Positive T-Lymphocytes,
pubmed-meshheading:10373067-Female,
pubmed-meshheading:10373067-Graft vs Host Disease,
pubmed-meshheading:10373067-Hematologic Diseases,
pubmed-meshheading:10373067-Humans,
pubmed-meshheading:10373067-Leukemia,
pubmed-meshheading:10373067-Lymphocyte Activation,
pubmed-meshheading:10373067-Lymphocyte Depletion,
pubmed-meshheading:10373067-Lymphoma,
pubmed-meshheading:10373067-Male,
pubmed-meshheading:10373067-Middle Aged,
pubmed-meshheading:10373067-Receptors, OX40,
pubmed-meshheading:10373067-Receptors, Tumor Necrosis Factor,
pubmed-meshheading:10373067-T-Lymphocytes,
pubmed-meshheading:10373067-Transplantation, Autologous,
pubmed-meshheading:10373067-Transplantation, Homologous
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation.
|
|
pubmed:affiliation |
Department of Hematology, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
|
|
pubmed:publicationType |
Journal Article
|
